Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.

After a series of deaths in patients taking Sarepta Therapeutics’ gene therapies, doubt has crept into investor sentiments ...

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the U.S. Food and Drug Administration (FDA ...

A milestone in the treatment of Duchenne muscular dystrophy (DMD) passed recently with remarkably little public notice. That ...

Surgical correction of scoliosis in patients with DMD remains controversial. This retrospective study enrolled patients who underwent posterior instrumented spinal fusion to correct spinal deformity ...

Your muscles need continuous maintenance to stay strong and healthy. Duchenne muscular dystrophy (DMD) happens when there is a change in a person's genetic instructions that affects the production of ...

"The incidence of DMD in our study was similar to that reported in previous studies . . . Overall, our results indicate that newborn screening for DMD is feasible, and this will be good news for the ...

From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and research. This year’s top stories on Duchenne muscular dystrophy (DMD) managed ...

Duchenne muscular dystrophy (DMD) is a genetic condition that causes increasing muscle weakness over time. While DMD currently has no cure, researchers are studying potential new treatments. When ...

ETHealthworld.com brings latest duchenne muscular dystrophy news, views and updates from all top sources for the Indian Health industry.

Cell and gene therapy company ENCell said on the 6th that its allogeneic umbilical cord-derived mesenchymal stem cell therapy candidate "EN001" received orphan drug designation (ODD) from the U.S.

Each of 15 shares of the company’s common stock outstanding was combined into one new share of common stock. ・No fractional ...